

Pathophysiology of Acute Kidney Injury

Joseph V. Bonventre MD PhD

Department of Medicine

Nephrology Division


Brigham and Women's Hospital, MassGeneralBrigham

Distinguished Samuel A. Levine Professor of Medicine

Harvard Medical School

Past-President, American Society of Nephrology

Joseph V Bonventre, MD, PhD



Harvard Medical School
Medicine Residency @ Massachusetts General Hosp.
Nephrology Fellowship @MGH
Professor of Medicine@ HMS
Chief Emeritus, Nephrology Division, MassGenBrigham
Founding Chief, Division of Engineering in Med. BWH
Research focus:
- Kidney Injury, Repair and Regeneration

DISCLOSURES

Advisory Board/Consultant: Praxis, Sarepta
Mitsubishi Tanabe, Nimbus, Otsuka, Dynamicure,
Verge Genomics, Kiora, Mediar, Crinetics, PepGen

Equity: Innoviva, Pacific Biosciences, MediBeacon
Autonomous Medical Devices Inc

Patents: Co-Inventor on KIM-1 patents assigned to
Partners Healthcare



OBJECTIVES

To better understand


- The pathophysiology of ischemic and toxic acute kidney injury.
- The implications of this pathophysiology for progression to chronic kidney disease and approach to therapy.



Pathophysiology of Acute Kidney Injury

- > Definitions
- > Pathophysiology of Injury
 - Tubules
 - Blood Vessels
 - Inflammation
- > Maladaptive Repair leading to Chronic Kidney Disease
- > Therapeutic Approaches Motivated by Pathobiology

Hospital survival, stratified by KDIGO stages of acute kidney injury



Chertow
Burdick
Honour
Bonventre
Bates
JASN 16:
3365-70, 2005

KDIGO Definition of AKI

Acute kidney injury is defined when one of the following criteria is met:

- > Serum creatinine rises by $\geq 26\mu\text{mol/L}$ (0.3 mg/dl) within 48 hours or
- > Serum creatinine rises ≥ 1.5 fold from the reference value, which is known or presumed to have occurred within 7 days or
- > Urine output is $< 0.5 \text{ ml/kg/hr}$ for >6 consecutive hours

KDIGO = **K**idney **D**isease to **I**mprove **G**lobal **O**utcomes

KDIGO staging system for acute kidney injury

Stage	Increase in serum creatinine	Urine output
1	➤0.3mg/dL increase in 48 hr; 1.5-1.9 > ref SCr	< 0.5 mL/kg/hr for > 6 h
2	≥ 2.0 to 2.9 X ref SCr	< 0.5 mL/kg/hr for > 12 h
3	≥ 3.0 X ref SCr or commenced on renal replacement therapy irrespective of stage > 0.5 mg/dL	< 0.3 mL/kg/hr for > 24 h or anuria for > 12 h

What Has Held Up Progress

Definition of AKI relies on Δ sCreat

- Serum creatinine rises by $\geq 26\mu\text{mol/L}$ (0.3 mg/dl) within 48 hrs or
- Serum creatinine rises ≥ 1.5 fold from the reference value, which is known or presumed to have occurred within one week, or
- Urine output is $< 0.5\text{ml/kg/hr}$ for > 6 consecutive hours

BUT


Acute kidney injury $\neq$ Acute tubular/interstitial injury

We want biomarkers that measure tubular-interstitial injury

Creatinine is a poor marker of AKI

- Production and release into circulation is highly variable with age, gender, meat intake, muscle mass, disease
- 10-40% is due to tubular excretion
- Drugs can inhibit tubular secretion (eg cimetidine and trimethoprim)
- Assay is subject to interference (e.g. acetoacetate, hyperbilirubinemia)
- Time delay in reflecting injury to the kidney
- Nonlinear relationship to fall in GFR impairs sensitivity
- Creatinine can increase in functional states without damage

Incidence of Kidney Dysfunction/Injury >> AKI




AKI Criteria

+

- - - - -


-

Renal Functional Reserve



Modified from
Sharma, Mucino and Ronco
Nephron Clin Prac
127:94-100, 2014

Mean Urinary KIM-1 and NAG Levels During Cisplatin Treatments In Patients with Testicular Cancer




FDA Qualified Safety Biomarker Panel

Acronym	Name (Unique ID (Uniprot))	Description
CLU	Urinary Clusterin (P10909)	A heterodimeric highly conserved secreted glycoprotein expressed in the proximal and distal tubules, glomerulus and collecting duct.
CysC	Cystatin-C (P01034)	A small serum protein produced by all nucleated cells and found in most tissues and body fluids. CysC is freely filtered by the glomerulus and completely reabsorbed and catabolized in healthy renal tubular epithelium.
KIM-1	Kidney Injury Molecule -1 (Q96D42)	A type I transmembrane glycoprotein containing an ectodomain consisting of an immunoglobulin-like domain and a mucin domain that is strongly induced by ischemic and toxic insults to the kidney.
NAG	N-acetyl-beta-D-glucosaminidase (O60502)	A large lysosomal enzyme with two isoforms and is mainly expressed in proximal tubules.
NGAL	Neutrophil gelatinase-associated lipocalin (P80188)	Expressed in various tissues at low levels with upregulated transcription in tubuloepithelial cells following ischemic and nephrotoxic kidney injuries.
OPN	Osteopontin (P10451)	A highly acidic glycoprotein expressed by many tissues that acts as a macrophage adhesion and chemotactic molecule.


Pathophysiology of Acute Kidney Injury

- > Definitions
- > Pathophysiology of Injury
 - Tubules
 - Blood Vessels
 - Inflammation
- > Maladaptive Repair leading to Chronic Kidney Disease
- > Therapeutic Approaches Motivated by Pathobiology

Acute Kidney Injury



Some mechanisms involved in initial tissue injury and subsequent repair of the kidney after acute kidney injury



Intravascular Volume Depletion and Hypotension

Gastrointestinal, renal, dermal losses, and hemorrhage

Decreased Effective Intravascular Volume

Congestive heart failure, cirrhosis, nephrosis, peritonitis

Medications

Cyclosporin A, tacrolimus, angiotensin converting enzyme inhibitors, nonsteroidal anti-inflammatory drugs, radiocontrast agents, amphotericin

Hepatorenal Syndrome


Renal Vascular Disease

Large vessel

Renal artery thrombosis, arterial occlusion during surgery, renal artery stenosis

Small vessel

Vasculitis, atheroembolism, hemolytic uremic syndrome/ thrombotic thrombocytopenic purpura, malignant hypertension, scleroderma, preeclampsia, sickle cell anemia, hypercalcemia, transplant rejection, other glomerular diseases with efferent blood flow impairment



Generalized or Localized Reduction in Renal Blood Flow

Acute Kidney Injury

Kidney Pathology in Patients Dying of Sepsis

Statement from Literature
That Underestimates the
Importance of Tubular Injury
In Sepsis induced AKI


“Renal tubular injury is common in sepsis but presents focally: Most renal tubular cells appear normal. The degree of cell injury and death does not account for severity of sepsis-induced organ dysfunction.”

- Proximal tubule vacuolization: 77% of septic patients
- KIM-1 expression: 32.3% corticomedullary junction
19.6% cortical labyrinth tubules


Takasu....Hotchkiss Am J Resp Crit Care Med.
187:509-517, 2013

Beeuwkes and Bonventre,
Am. J. Physiol., 1975

Complexity of Proximal Tubule





Nephron, corticomedullary oxygen gradient, and microvascular anatomy.





Endothelial and Epithelial Injury and Glycocalyx Disruption in AKI



Normal



Post AKI




Perfusion Maps of the Mouse Kidney using Contrast-Enhanced Ultrasound




Pre-I/R 15 min 30 min 45 min 60 min 24 hr Post-I/R

Endothelial and Epithelial Injury, Inflammation and AKI




Simplified Pathobiology of AKI




Normally a cell can undergo >1 million DNA changes per day.

(Lodish et al, Mol Bio Cell)

Fluid may be very bad for AKI



Effects of Fluid Overload on Organ Systems



Fluid Management in Septic Patients at Risk of AKI

According to the Surviving Sepsis Campaign guidelines,
which type of fluid is recommended for initial resuscitation
Of patients with sepsis-induced hypoperfusion and AKI

- A. Buffered solutions (Ringer's lactate, Hartmann's solution, Plasma Lyte)
- B. 5% Albumin
- C. 0.9% saline.
- D. Starch, gelatin and dextrans

Fluid Therapy for Patients at Risk of Acute Kidney Injury


General Principle: In AKI oliguria is not an indication for fluid administration. Intravascular hypovolemia should be the only indication. Optimal fluid composition has not been defined.

Crystalloids: Buffered solutions (Ringer's lactate, Hartmann's solution, Plasma Lyte) are recommended for patients at risk of AKI who are not hypochloremic.

0.9% saline is recommended for only hypovolemic, hypochloremic patients (with close monitoring of chloride)

Colloids: Gelatin based fluids should be avoided
Albumin does not provide a survival benefit compared with crystalloid.
Albumin decreases fluid requirements for resuscitation but does not reduce the need for RRT.
Starch should be avoided.

Pathophysiological Features of Cardiac Damage after Acute Kidney Injury



Pathophysiology of Acute Kidney Injury

- > Definitions
- > Pathophysiology of Injury
 - Tubules
 - Blood Vessels
 - Inflammation
- > Maladaptive Repair leading to Chronic Kidney Disease
- > Therapeutic Approaches Motivated by Pathobiology

AKI Leads to CKD


AKI




CKD

CKD Predisposes to AKI


Natural history of acute kidney injury (AKI).



Meta-analysis of the risk of Chronic Kidney Disease after AKI



Maladaptive repair of AKI leads to CKD



Multimodal single-cell and Spatial Atlas: Integrated Transcriptomics, Epigenomic and Imaging Data from Three Major Consortia (HuBMAP, KPMP and Human Cell Atlas)

- ❑ Putative adaptive or maladaptive repair signatures within the epithelial segments ...may reflect a failure to complete differentiation and tubulogenesis.
- ❑ Epithelial repair states have elevated cytokine production, increased interactions with the distinct fibrotic and inflammatory cell types, and expression signatures linked to senescence and progression to end-stage kidney disease.
- ❑ Failure of these cells to complete tubulogenesis...might ultimately contribute to a progressive decline in kidney function.
- ❑ The high-cytokine-producing nature of these cells may further contribute to kidney disease through promotion of fibrosis.

Pathophysiology of Acute Kidney Injury


- > Definitions
- > Pathophysiology of Injury
 - Tubules
 - Blood Vessels
 - Inflammation
- > Maladaptive Repair leading to Chronic Kidney Disease
- > Therapeutic Approaches Motivated by Pathobiology

Effects of SGLT2 Inhibitors on Acute Kidney Injury

Which Statement(s) is (are) correct?


- ☐ SGLTi's predispose to volume depletion and AKI
- ☐ SGLTi's have been shown to reduce the incidence of AKI

Meta-analysis SGLT2i Effects on Acute Kidney Injury (13 Trials)




The Neuffield Department of Population Health Renal Studies Group and The SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists Consortium. Lancet 400: 1788-1801, 2022


SGLT2 Inhibitor Effects on Hemodynamics and Oxygenation




Bergman et al (U. of Iowa)




SGLT2 inhibitors



Empagliflozin



Canagliflozin



Dapagliflozin

Other SGLT2i

Potential Protective Mechanisms

AMPK



Autophagy



KIM-1



Apoptosis



p53 / p21



Cellular Senescence



GSK-3 β



Inflammatory Cytokines



HIF-1 α
HE4 / NF- κ B



Fibrosis



NRF2/HO-1



ROS



PINK1



Mitophagy



CoRL




Glomerular Regeneration




Renoprotective effect


Injury



Early Adaptive Repair


CKD





Na Bicarbonate in Metabolic Acidotic Patients on Pressors in the ICU


In-Hospital Survival by Day 30



No. at Risk

Sodium bicarbonate	244	205	141	97	66	46	39
Placebo	254	208	140	103	76	55	48

Renal Replacement Therapy by Day 30



No. at Risk

Sodium bicarbonate	244	175	109	67	45	32	27
Placebo	254	174	106	73	56	36	32


Conventional (3X/wk) vs Conservative Dialysis for AKI

LIBERATE-D

Baseline eGFR:
65ml/min/1.73m²

Subjects started
Dialysis a median
of 9 days before
randomization

Conservative group:
Dialysis only when
specific metabolic and
clinical criteria were met



No. of patients without kidney
function recovery

Conservative dialysis	109	45	36	33	31	31	31	30	30	30
Conventional thrice-weekly dialysis	109	65	54	49	47	46	46	45	45	45

Some Currently Studied Therapeutics for AKI and Pathobiology Targeted

Anti-inflammatory

Alkaline Phosphatase
 α -MSH analogs (ABT-719)
Complement Inhibitors
DPP-4 Inhibitors
CD28 antagonists
Sphingosine-1-P analogs
Anti-IL6 antibodies
Heme arginate
Mesenchymal Stem Cells
Extracellular Vesicles
Remove monocytes/neutrophils

Improve Mitochondria

Nicotinamide Adenine Dinucleotide
Cardiolipin

Anti-oxidants

Iron chelators
NGAL
Heme arginate
Bardoxalone
Propofol
Curcumin
 α -lipoic acid
NOX inhibitors

Vasoactive

Angiotensin II
Levosimendan

Senolytic

Navitoclax

Facilitate Regeneration

Hepatocyte Growth Factor
BMP receptor agonists

? Cell Cycle/ ? Cell Death

P53 siRNA

Take Home Messages

To Develop New Therapies for Human AKI

We need:

- ◆ More efficient ways to select high risk patients
-GFR, Renal Reserve, with other clinical features
- ◆ Qualification of blood and urine biomarkers using better ways to determine kidney injury than by using creatinine
- ◆ New non-invasive tools to interrogate metabolism, cellular repair response and pathobiology, particularly endothelial pathology
- ◆ Animal models which incorporate underlying co-morbidities that characterize our patients.
- ◆ Human tissue obtained at well characterized stages of early AKI
- ◆ Human tissue models to mimic AKI and AKI►CKD
- ◆ Cell type specific characterization of the human tissue
- ◆ Better understanding of effects of genetics predisposition to AKI and propensity to maladaptive repair humans

References

Barasch J, Zager R, Bonventre JV. [Acute kidney injury: a problem of definition](#). Lancet 389: 779-781, 2017

Yu SM, Bonventre JV. [Acute kidney injury and maladaptive tubular repair leading to renal fibrosis](#). Curr Opin Nephrol Hypertens. 29:310-318, 2020

Lake BB et al. [An atlas of healthy and injured cell states and niches in the human kidney](#). Nature 619: 585-594, 2023

Ostermann M et al. [Acute Kidney Injury](#). Lancet 405: 241-256, 2025

Thank You